Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nanda K, Moss AC
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/700ef8beae274ebe9effe74d841de870
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:700ef8beae274ebe9effe74d841de870
record_format dspace
spelling oai:doaj.org-article:700ef8beae274ebe9effe74d841de8702021-12-02T01:24:44ZUpdate on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine1179-1438https://doaj.org/article/700ef8beae274ebe9effe74d841de8702012-07-01T00:00:00Zhttp://www.dovepress.com/update-on-the-management-of-ulcerative-colitis-treatment-and-maintenan-a10508https://doaj.org/toc/1179-1438Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System® (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda® or Mezavant®, Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy.Keywords: mesalamine, 5-ASA, ulcerative colitis, inflammatory bowel diseaseNanda KMoss ACDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2012, Iss default, Pp 41-50 (2012)
institution DOAJ
collection DOAJ
language EN
topic Therapeutics. Pharmacology
RM1-950
spellingShingle Therapeutics. Pharmacology
RM1-950
Nanda K
Moss AC
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
description Kavinderjit Nanda, Alan C MossCenter for Inflammatory Bowel Disease, BIDMC/Harvard Medical School, Boston, MA, USAAbstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System® (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda® or Mezavant®, Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy.Keywords: mesalamine, 5-ASA, ulcerative colitis, inflammatory bowel disease
format article
author Nanda K
Moss AC
author_facet Nanda K
Moss AC
author_sort Nanda K
title Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
title_short Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
title_full Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
title_fullStr Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
title_full_unstemmed Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
title_sort update on the management of ulcerative colitis: treatment and maintenance approaches focused on mmx® mesalamine
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/700ef8beae274ebe9effe74d841de870
work_keys_str_mv AT nandak updateonthemanagementofulcerativecolitistreatmentandmaintenanceapproachesfocusedonmmxampregmesalamine
AT mossac updateonthemanagementofulcerativecolitistreatmentandmaintenanceapproachesfocusedonmmxampregmesalamine
_version_ 1718403080025800704

Ejemplares similares